- Report
- April 2025
- 175 Pages
Global
From €3941EUR$4,490USD£3,429GBP
- Report
- September 2025
- 143 Pages
Global
From €3510EUR$3,999USD£3,054GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1756EUR$2,000USD£1,527GBP
- Report
- June 2025
- 400 Pages
Global
From €4344EUR$4,949USD£3,779GBP
- Report
- June 2025
- 200 Pages
Global
From €2448EUR$2,789USD£2,130GBP
- Report
- June 2020
- 753 Pages
Global
From €1883EUR$2,145USD£1,638GBP
€2897EUR$3,300USD£2,520GBP
- Report
- February 2024
- 111 Pages
Global
From €4169EUR$4,750USD£3,627GBP
Acalabrutinib is a type of oncology drug used to treat certain types of cancer. It is a Bruton's tyrosine kinase (BTK) inhibitor, which works by blocking the activity of BTK, a protein that helps certain cancer cells to grow and spread. Acalabrutinib is used to treat mantle cell lymphoma, a type of non-Hodgkin's lymphoma, and chronic lymphocytic leukemia (CLL). It is also being studied for use in other types of cancer.
Acalabrutinib is available in tablet form and is taken orally. Common side effects include diarrhea, nausea, fatigue, and muscle or joint pain. More serious side effects may include an increased risk of infection, bleeding, and low blood cell counts.
Acalabrutinib is marketed by several companies, including AstraZeneca, Gilead Sciences, and AbbVie. Show Less Read more
